(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 13.69% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Cytosorbents's revenue in 2024 is $36,349,379.On average, 3 Wall Street analysts forecast CTSO's revenue for 2024 to be $2,187,650,212, with the lowest CTSO revenue forecast at $2,145,138,358, and the highest CTSO revenue forecast at $2,242,323,822. On average, 3 Wall Street analysts forecast CTSO's revenue for 2025 to be $2,592,680,132, with the lowest CTSO revenue forecast at $2,394,345,776, and the highest CTSO revenue forecast at $2,701,647,297.
In 2026, CTSO is forecast to generate $2,841,724,669 in revenue, with the lowest revenue forecast at $2,841,724,669 and the highest revenue forecast at $2,841,724,669.